PEN Penumbra Inc
$320.55
▼ 0.2%Updated Oct 16, 2:25 PM ET
Report Card
PEN at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Neutral · 52/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 26.5% in the year to Jul 6, 2026
Key Metrics
Market Cap
$12.53B
P/E
73.25x
Forward P/E (est.)
52.32x
ROE
12.3%
Revenue Growth
17.3%
EPS Growth
323.6%
Profit Margin
11.8%
FCF Yield
0.5%
Debt / Equity
0.02x
ROIC
10.0%
Interest Coverage
108.83x
Current Ratio
5.75x
Dividend Yield
—
Implied Growth (rev. DCF)
7.5%
Rating Score
52/100
Business Overview
Penumbra Inc (PEN) is a large-cap NYSE-listed company in the Health Care industry, within the Health Care sector, with a market value around $12.53B.
In its latest reported year it generated about $1.40B in revenue and $177.69M in net profit.
Our model rates PEN Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedThe filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
64.9% average over the last 3 years
±2.1 pts around 64.6% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 6 of 10 years
10.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what PEN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. PEN trades near $320.55, around its 50-day average ($321.64) and 200-day average ($309.55). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 46 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. PEN's is $2.14 (~0.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, PEN found buyers near $314.80 (support) and sellers near $322.65 (resistance); its 52-week range then was $221.26–$362.41. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
17.1%
Revenue moved from $263.32M in 2016 to $1.40B in 2025, a 20.4% compound annual growth rate. The most recent year grew a strong 17.3% year over year. Consistent top-line growth is one sign of healthy demand.
Profitability
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
ROE
12.3%
Penumbra Inc keeps about 11.8% of each sales dollar as net profit, with a 67.1% gross margin and 13.5% operating margin. Return on equity is 12.3% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Debt Analysis
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0.02x
Leverage: debt-to-equity is 0.0x, and operating profit covers interest about 108.8x, with a current ratio of 5.8x. That is a conservative balance sheet — a cushion in downturns.
Cash Flow Analysis
Operating CF
$238.66M
Free Cash Flow
$174.93M
FCF Margin
12.5%
In the latest year Penumbra Inc produced about $238.66M of operating cash flow and $174.93M of free cash flow after capital spending. That is a free-cash-flow yield of about 0.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
73.25x
P/S
8.93x
P/B
8.53x
EV / EBITDA
59.62x
PEN trades at 73.3x trailing earnings (about 52.3x on estimated forward earnings), 8.9x sales, and 8.5x book value. Reverse-engineering today's price implies the market expects roughly 7.5% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$158.88
Current price
$320.55
Starting FCF (latest 10-K)
$174.93M
Growth, years 1–5
17.3%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where PEN sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How PEN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, PEN ranks #41 by our overall rating. It trades at a premium versus the sector on earnings (73.3x P/E vs. 26.1x median) with a lower return on equity (12.3% vs. 14.1%) and faster revenue growth (17.3% vs. 7.6%).
P/E vs sector
73.3x
median 26.1x
ROE vs sector
12.3%
median 14.1%
Growth vs sector
17.3%
median 7.6%
Sector rank
#41
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$450.34 – $747.15
vs. $320.55 today · implied CAGR 7% – 18%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.64B | $1.92B | $2.25B | $2.63B | $3.08B |
| Net income | $213.50M | $249.79M | $292.26M | $341.94M | $400.07M |
| EPS | $5.46 | $6.39 | $7.48 | $8.75 | $10.23 |
| Share price (low) | $240.32 | $281.18 | $328.98 | $384.91 | $450.34 |
| Share price (high) | $398.72 | $466.50 | $545.81 | $638.59 | $747.15 |
| CAGR (low–high) | -25% / 24% | -6% / 21% | 1% / 19% | 5% / 19% | 7% / 18% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for PEN:
- Revenue is growing 17.3% a year, a sign of real demand.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
Bear Case
The case against PEN:
- A rich 73.3x earnings multiple prices in a lot of growth.
- Limited free cash flow at today's price.
Key Risks
Valuation risk — at 73.3x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the picture is mixed: Penumbra Inc is a large-cap health care business still growing nicely, with modest profitability, and a sound balance sheet. It trades at 73.3x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 20 Wall Street analysts covering PEN recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-3 pts of buy ratings).
Latest SEC Filings
PEN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
PEN — frequently asked questions
Is PEN a good stock to buy?
We don't give buy or sell advice. Our model rates Penumbra Inc Neutral (52/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is PEN's rating on The Stocks School?
Penumbra Inc currently scores 52/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does PEN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Penumbra Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for PEN calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this PEN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell PEN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.